Advertisement

Molecular Medicine

, Volume 21, Issue 1, pp 626–636 | Cite as

Angiotensin-(1–1) Suppresses Hepatocellular Carcinoma Growth and Angiogenesis via Complex Interactions of Angiotensin II Type 1 Receptor, Angiotensin II Type 2 Receptor and Mas Receptor

  • Yanping Liu
  • Bin Li
  • Ximing Wang
  • Guishuang Li
  • Rui Shang
  • Jianmin Yang
  • Jiali Wang
  • Meng Zhang
  • Yuguo Chen
  • Yun Zhang
  • Cheng Zhang
  • Panpan Hao
Research Article

Abstract

We recently confirmed that angiotensin II (Ang II) type 1 receptor (AT1R) was overexpressed in hepatocellular carcinoma tissue using a murine hepatoma model. Angiotensin(Ang)-(1-7) has been found beneficial in ameliorating lung cancer and prostate cancer. Which receptor of Ang-(1-7) is activated to mediate its effects is much speculated. This study was designed to investigate the effects of Ang-(1-7) on hepatocellular carcinoma, as well as the probable mechanisms. H22 hepatoma-bearing mice were randomly divided into five groups for treatment: mock group, low-dose Ang-(1-7), high-dose Ang-(1-7), high-dose Ang-(1-7) + A779 and high-dose Ang-(1-7) + PD123319. Ang-(1-7) treatment inhibited tumor growth time- and dose-dependently by arresting tumor proliferation and promoting tumor apoptosis as well as inhibiting tumor angiogenesis. The effects of Ang-(1-7) on tumor proliferation and apoptosis were reversed by coadministration with A779 or PD123319, whereas the effects on tumor angiogenesis were completely reversed by A779 but not by PD123319. Moreover, Ang-(1-7) downregulated AT1R mRNA, upregulated mRNA levels of Ang II type 2 receptor (AT2R) and Mas receptor (MasR) and p38-MAPK phosphorylation and suppressed H22 cell-endothelial cell communication. Thus, Ang-(1-7) administration suppresses hepatocellular carcinoma via complex interactions of AT1R, AT2R and MasR and may provide a novel and promising approach for the treatment of hepatocellular carcinoma.

Notes

Acknowledgments

This work was supported by the National 973 Basic Research Program of China (grants 2011CB503906, 2012CB518603), the National High-Tech Research and Development Program of China (grant 2012AA02A510), the Program of Introducing Talents of Discipline to Universities (grant B07035), the State Program of National Natural Science Foundation of China for Innovative Research Group (grant 81021001), the National Natural Science Foundation of China (grants 81400284, 81371548, 81320108004, 61331001) and the Natural Science Foundation of Shandong Province (grants ZR2014HM044, ZR2014HP045).

References

  1. 1.
    George AJ, Thomas WG, Hannan RD. (2010) The renin angiotensin system and cancer: Old dog, new tricks. Nat. Rev. Cancer. 10:745–59.CrossRefGoogle Scholar
  2. 2.
    Wegman-Ostrosky T, Soto-Reyes E, Vidal-Millán S, Sánchez-Corona J. (2015) The renin-angiotensin system meets the hallmarks of cancer. J. Renin Angiotensin Aldosterone Syst. 16:227–33.CrossRefGoogle Scholar
  3. 3.
    Chauhan VP, et al. (2013) Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat. Commun. 4:2516.CrossRefGoogle Scholar
  4. 4.
    Sevá Pessôa B, et al. (2013) Key developments in renin-angiotensin-aldosterone system inhibition. Nat. Rev. Nephrol. 9:26–36.CrossRefGoogle Scholar
  5. 5.
    Soto-Pantoja DR, Menon J, Gallagher PE, Tallant EA. (2009) Angiotensin-(1-7) inhibits tumor angiogenesis in human lung cancer xenografts with a reduction in vascular endothelial growth factor. Mol. Cancer Ther. 8:1676–83.CrossRefGoogle Scholar
  6. 6.
    Krishnan B, et al. (2013) Angiotensin-(1-7) attenuates metastatic prostate cancer and reduces osteoclastogenesis. Prostate. 73:71–82.CrossRefGoogle Scholar
  7. 7.
    Hao PP, et al. (2014) Evaluation of (131)I-anti-angiotensin II type 1 receptor monoclonal antibody as a reporter for hepatocellular carcinoma. PLoS One. 9:e85002.CrossRefGoogle Scholar
  8. 8.
    Cai L, Li W, Wang G, Guo L, Jiang Y, Kang YJ. (2002) Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome C-mediated caspase-3 activation pathway. Diabetes. 51:1938–48.CrossRefGoogle Scholar
  9. 9.
    Cook KL, Metheny-Barlow LJ, Tallant EA, Gallagher PE. (2010) Angiotensin-(1-7) reduces fibrosis in orthotopic breast tumors. Cancer Res. 70:8319–28.CrossRefGoogle Scholar
  10. 10.
    Hida T, et al. (1989) Chemosensitivity and radiosensitivity of small cell lung cancer cell lines studied by a newly developed 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) hybrid assay. Cancer Res. 49:4785–90.PubMedGoogle Scholar
  11. 11.
    Herrera M, Sparks MA, Alfonso-Pecchio AR, Harrison-Bernard LM, Coffman TM. (2013) Lack of specificity of commercial antibodies leads to misidentification of angiotensin type 1 receptor protein. Hypertension. 61:253–8.CrossRefGoogle Scholar
  12. 12.
    Hafko R, et al. (2013) Commercially available angiotensin II At2 receptor antibodies are nonspecific. PLoS One. 8:e69234.CrossRefGoogle Scholar
  13. 13.
    Michel MC, Wieland T, Tsujimoto G. (2009) How reliable are G-protein-coupled receptor antibodies? Naunyn Schmiedebergs Arch. Pharmacol. 379:385–8.CrossRefGoogle Scholar
  14. 14.
    Santos RA, Ferreira AJ, Verano-Braga T, Bader M. (2013) Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: New players of the renin-angiotensin system. J. Endocrinol. 216:1–17.CrossRefGoogle Scholar
  15. 15.
    Tesanovic S, Vinh A, Gaspari TA, Casley D, Widdop RE. (2010) Vasoprotective and atheroprotective effects of angiotensin (1-7) in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 30:1606–13.CrossRefGoogle Scholar
  16. 16.
    Freeman EJ, Chisolm GM, Ferrario CM, Tallant EA. (1996) Angiotensin-(1-7) inhibits vascular smooth muscle cell growth. Hypertension. 28:104–8.CrossRefGoogle Scholar
  17. 17.
    Tallant EA, Ferrario CM, Gallagher PE. (2005) Angiotensin-(1-7) inhibits growth of cardiac myocytes though activation of the mas receptor. Am. J. Physiol. Heart Circ. Physiol. 289:H1560–6.CrossRefGoogle Scholar
  18. 18.
    McCollum LT, Gallagher PE, Tallant EA. (2012) Angiotensin-(1-7) abrogates mitogen-stimulated proliferation of cardiac fibroblasts. Peptides. 34:380–8.CrossRefGoogle Scholar
  19. 19.
    Heringer-Walther S, et al. (2009) Angiotensin-(1-7) stimulates hematopoietic progenitor cells in vitro and in vivo. Haematologica. 94:857–60.CrossRefGoogle Scholar
  20. 20.
    Rhodes DR, et al. (2009) AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. Proc. Natl. Acad. Sci. U. S. A. 106:10284–9.CrossRefGoogle Scholar
  21. 21.
    Suganuma T, et al. (2005) Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumour invasion, angiogenesis, and peritoneal dissemination. Clin. Cancer Res. 11:2686–94.CrossRefGoogle Scholar
  22. 22.
    Lewandowska U, Lachowicz-Ochędalska A, Domińska K, Kaszewska D, Rębas E. (2011) Angiotensin II as a factor modulating protein tyrosine kinase activity in two breast cancer lines — MCF-7 and MDA-MB-231. Endokrynol. Pol. 62:151–8.PubMedGoogle Scholar
  23. 23.
    Zhao Y, et al. (2010) Angiotensin II/angiotensin II type I receptor (AT1R) signaling promotes MCF-7 breast cancer cells survival via PI3-kinase/Akt pathway. J. Cell Physiol. 225:168–73.CrossRefGoogle Scholar
  24. 24.
    Fujiyama S, et al. (2001) Angiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation. Circ. Res. 88:22–9.CrossRefGoogle Scholar
  25. 25.
    Du H, et al. (2013) Effects of angiotensin II type 2 receptor overexpression on the growth of hepatocellular carcinoma cells in vitro and in vivo. PLoS One. 8:e83754.CrossRefGoogle Scholar
  26. 26.
    Hu F, Morrissey P, Yao J, Xu Z. (2004) Development of AT(1) and AT(2) receptors in the ovine fetal brain. Brain Res. Dev. Brain Res. 150:51–61.CrossRefGoogle Scholar
  27. 27.
    Menon J, et al. (2007) Angiotensin-(1-7) inhibits growth of human lung adenocarcinoma xenografts in nude mice though a reduction in cyclooxygenase-2. Cancer Res. 67:2809–15.CrossRefGoogle Scholar
  28. 28.
    Gallagher PE, Tallant EA. (2004) Inhibition of human lung cancer cell growth by angiotensin-(1-7). Carcinogenesis. 25:2045–52.CrossRefGoogle Scholar
  29. 29.
    Li H, et al. (2009) Angiotensin type 2 receptor-mediated apoptosis of human prostate cancer cells. Mol. Cancer Ther. 8:3255–65.CrossRefGoogle Scholar
  30. 30.
    Shiao SL, Ganesan AP, Rugo HS, Coussens LM. (2011) Immune microenvironments in solid tumors: new targets for therapy. Genes Dev. 25:2559–72.CrossRefGoogle Scholar
  31. 31.
    Jiao H, et al. (2012) Human amniotic membrane derived-mesenchymal stem cells induce C6 glioma apoptosis in vivo though the Bcl-2/caspase pathways. Mol. Biol. Rep. 39:467–73.CrossRefGoogle Scholar
  32. 32.
    Srivastava MK, et al. (2012) Myeloid suppressor cell depletion augments antitumor activity in lung cancer. PLoS One. 7:e40677.CrossRefGoogle Scholar
  33. 33.
    Holmgren L, O’Reilly MS, Folkman J. (1995) Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med. 1:149–53.CrossRefGoogle Scholar
  34. 34.
    Schmaltz C, Hardenbergh PH, Wells A, Fisher DE. (1998) Regulation of proliferation-survival decisions during tumor cell hypoxia. Mol. Cell. Biol. 18:2845–54.CrossRefGoogle Scholar
  35. 35.
    Feng Y, et al. (2010) The angiotensin-converting enzyme 2 in tumor growth and tumor-associated angiogenesis in non-small cell lung cancer. Oncol. Rep. 23:941–8.PubMedGoogle Scholar
  36. 36.
    Bağışlar GS. (2009) Genetic and Epigenetic Analysis of Immortal and Senescence Arrested Liver Cancer Cells [dissertation]. Ankara (Turkey): Bilkent University. [cited 2015 Oct 26]. Available from: https://doi.org/www.thesis.bilkent.edu.tr/0006157.pdf.Google Scholar
  37. 37.
    Cao Y, et al. (2011) Forty-year journey of angiogenesis translational research. Sci. Transl. Med. 3:114rv3.PubMedGoogle Scholar
  38. 38.
    Soto-Pantoja DR, Petty WJ, Gallagher PE, Tallant EA. (2009) Angiotensin-(1-7) inhibits triple negative tumor growth though the inhibition of angiogenesis and a reduction in placental growth factor PIGF [abstract]. Cancer Res. 69:s103.CrossRefGoogle Scholar
  39. 39.
    Lin CY, et al. (2013) MiR-1 and miR-206 target different genes to have opposing roles during angiogenesis in zebrafish embryos. Nat. Commun. 4:2829.CrossRefGoogle Scholar
  40. 40.
    Dvorak HF. (2002) Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 20:4368–80.CrossRefGoogle Scholar
  41. 41.
    Krishnan B, Torti FM, Gallagher PE, Tallant EA. (2013) Angiotensin-(1-7) reduces proliferation and angiogenesis of human prostate cancer xenografts with a decrease in angiogenic factors and an increase in sFlt-1. Prostate. 73:60–70.CrossRefGoogle Scholar
  42. 42.
    Ambati BK, et al. (2006) Corneal avascularity is due to soluble VEGF receptor-1. Nature. 443:993–7.CrossRefGoogle Scholar
  43. 43.
    Harris AL. (2002) Hypoxia—a key regulatory factor in tumour growth. Nat. Rev. Cancer. 2:38–47.CrossRefGoogle Scholar
  44. 44.
    Berra E, et al. (2000) Signaling angiogenesis via p42/p44 MAP kinase and hypoxia. Biochem. Pharmacol. 60:1171–8.CrossRefGoogle Scholar
  45. 45.
    Tallant EA, Clark MA. (2003) Molecular mechanisms of inhibition of vascular growth by angiotensin-(1-7). Hypertension. 42:574–9.CrossRefGoogle Scholar
  46. 46.
    Tudisco L, et al. (2014) Epigenetic control of hypoxia inducible factor-1α-dependent expression of placental growth factor in hypoxic conditions. Epigenetics. 9:600–10.CrossRefGoogle Scholar
  47. 47.
    Petty WJ, et al. (2012) Reverse translation of phase I biomarker findings links the activity of angiotensin-(1-7) to repression of in vascular sarcomas. BMC Cancer. 12:404.CrossRefGoogle Scholar
  48. 48.
    Patel N, Kalra VK. (2010) Placenta growth factor-induced early growth response 1 (Egr-1) regulates hypoxia-inducible factor-1alpha (HIF-1alpha) in endothelial cells. J. Biol. Chem. 285:20570–9.CrossRefGoogle Scholar
  49. 49.
    Fischer C, et al. (2007) Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell. 131:463–75.CrossRefGoogle Scholar
  50. 50.
    Hedlund EM, et al. (2013) Tumor cell-derived placental growth factor sensitizes antiangiogenic and antitumor effects of anti-VEGF drugs. Proc. Natl. Acad. Sci. U. S. A. 110:654–9.CrossRefGoogle Scholar
  51. 51.
    Yang X, et al. (2013) Vascular endothelial growth factor-dependent spatiotemporal dual roles of placental growth factor in modulation of angiogenesis and tumor growth. Proc. Natl. Acad. Sci. U. S. A. 110:13932–7.CrossRefGoogle Scholar
  52. 52.
    Jones MK, et al. (1999) Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat. Med. 5:1418–23.CrossRefGoogle Scholar
  53. 53.
    Gately S, Li WW. (2004) Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin Oncol. 31:2–11.CrossRefGoogle Scholar
  54. 54.
    Iñiguez MA, Rodríguez A, Volpert OV, Fresno M, Redondo JM. (2003) Cyclooxygenase-2: a therapeutic target in angiogenesis. Trends Mol. Med. 9:73–8.CrossRefGoogle Scholar
  55. 55.
    Miyata Y, et al. (2003) Expression of cyclooxygenase-2 in renal cell carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, expression of matrix metalloproteinase-2, and survival. Clin Cancer Res. 9:1741–9.PubMedGoogle Scholar
  56. 56.
    Röcken C, et al. (2007) The angiotensin II/angiotensin II receptor system correlates with nodal spread in intestinal type gastric cancer. Cancer Epidemiol. Biomarkers Prev. 16:1206–12.CrossRefGoogle Scholar
  57. 57.
    Kosaka T, et al. (2010) Ets-1 and hypoxia inducible factor-1alpha inhibition by angiotensin II type-1 receptor blockade in hormone-refractory prostate cancer. Prostate. 70:162–9.PubMedGoogle Scholar
  58. 58.
    Clere N, et al. (2010) Deficiency or blockade of angiotensin II type 2 receptor delays tumourigenesis by inhibiting malignant cell proliferation and angiogenesis. Int. J. Cancer. 127:2279–2291.CrossRefGoogle Scholar
  59. 59.
    Zhao W, Zhao T, Chen Y, Sun Y. (2015) Angiotensin 1-7 promotes cardiac angiogenesis following infarction. Curr. Vasc. Pharmacol. 13:37–42.CrossRefGoogle Scholar
  60. 60.
    Cao Y. (2014) VEGF-targeted cancer therapeutics-paradoxical effects in endocrine organs. Nat. Rev. Endocrinol. 10:530–9.CrossRefGoogle Scholar
  61. 61.
    Ng IO, Poon RT, Lee JM, Fan ST, Ng M, Tso WK. (2001) Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma. Am. J. Clin. Pathol. 116:838–45.CrossRefGoogle Scholar
  62. 62.
    Choi WW, et al. (2005) Angiogenic and lymphangiogenic microvessel density in breast carcinoma: correlation with clinicopathologic parameters and VEGF-family gene expression. Mod. Pathol. 18:143–52.CrossRefGoogle Scholar

Copyright information

© The Author(s) 2015

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.

The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this license, visit (https://doi.org/creativecommons.org/licenses/by-nc-nd/4.0/)

Authors and Affiliations

  • Yanping Liu
    • 1
    • 2
  • Bin Li
    • 3
  • Ximing Wang
    • 2
  • Guishuang Li
    • 1
  • Rui Shang
    • 1
  • Jianmin Yang
    • 1
  • Jiali Wang
    • 1
  • Meng Zhang
    • 1
  • Yuguo Chen
    • 1
  • Yun Zhang
    • 1
  • Cheng Zhang
    • 1
  • Panpan Hao
    • 1
  1. 1.The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, Qilu HospitalShandong UniversityShandongChina
  2. 2.Shandong Key Laboratory of Cardiovascular and Cerebrovascular Disease, Shandong Provincial Medical Imaging InstituteShandong UniversityShandongChina
  3. 3.Jinan Central HospitalAffiliated with Shandong UniversityJinan, ShandongChina

Personalised recommendations